These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 20087037

  • 1. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M, Hoshino S, Noda N, Nakano M, Matsuo K, Yamauchi Y, Shinohara T, Tanaka S, Yamashita Y.
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
    [Abstract] [Full Text] [Related]

  • 2. [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
    Koyama M, Murata A, Kimura Y, Sakamoto Y, Morohashi H, Kimura N, Gasa F, Sato J, Terui K, Awatsu A, Hakamada K.
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1069-73. PubMed ID: 20567110
    [Abstract] [Full Text] [Related]

  • 3. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S, AVIRI Trial investigators.
    Oncology; 2009 Jun; 77(2):113-9. PubMed ID: 19628950
    [Abstract] [Full Text] [Related]

  • 4. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
    Yoshida Y, Hasegawa J, Nishimura J, Hirota M, Kim Y, Nezu R.
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S, Moreno C, Medina J, Pérez-García B, García-López JL, Jaén P.
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH, Jensen BV, Larsen FO.
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H.
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [Abstract] [Full Text] [Related]

  • 15. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M.
    Cancer Biomark; 2009 Oct; 5(4):167-75. PubMed ID: 19729826
    [Abstract] [Full Text] [Related]

  • 16. The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
    Terazawa T, Nishitani H, Kato K, Hashimoto H, Akiyoshi K, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Shimada Y.
    Anticancer Res; 2014 Feb; 34(2):1053-6. PubMed ID: 24511054
    [Abstract] [Full Text] [Related]

  • 17. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
    Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J.
    Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, Koike K, Ohtsu A.
    Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
    [Abstract] [Full Text] [Related]

  • 19. [Analysis of hypertension in advanced, recurrent colorectal cancer patients treated with first-line bevacizumab].
    Yamamura K, Ishigure K.
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):85-8. PubMed ID: 21368463
    [Abstract] [Full Text] [Related]

  • 20. Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
    Usui K, Katou Y, Furushima K, Tanaka Y, Tanai C, Ishihara T.
    Jpn J Clin Oncol; 2011 Apr; 41(4):498-502. PubMed ID: 21303791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.